The PD-MIND (Parkinson’s disease with mild cognitive impairment treated with nicotinic agonist drug) project aims to develop a treatment for PD-MCI, by means of a clinical study involving a potential new drug thought to improve memory, learning and thought processes.
PD-MIND is a phase 2a, randomized, double-blind, placebo-controlled, parallel-group designed study. It is an international multi-centre study with 10 study sites in Europe: UK, Italy, Germany, Czech Republic and Norway. 160 individuals with PD-MCI will be recruited and randomised: 80 in an active (AZD0328) group and 80 in a control (placebo) group. A subset of 90 participants will have MRI scans taken at their study entry and exit in order to compare pictures of the brain before and after taking study medication.